A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas

Nicole Foley; Peter A Riedell; Nancy L Bartlett; Amanda F Cashen; Brad S Kahl; Todd A Fehniger; Anne Fischer; Chaz Moreno; Jingxia Liu; Kenneth R Carson; Neha Mehta-Shah

doi:10.1016/j.clml.2024.11.015

A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas

Clin Lymphoma Myeloma Leuk. 2024 Dec 4:S2152-2650(24)02436-4. doi: 10.1016/j.clml.2024.11.015. Online ahead of print.

Authors

Affiliations

¹ Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
² Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
³ Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; Department of Medicine, Northwestern University, Chicago, IL.
⁴ Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Electronic address: mehta-n@wustl.edu.

PMID: 39725584
DOI: 10.1016/j.clml.2024.11.015

Abstract

Introduction: Histone deacetylase inhibitors (HDACi) and combination chemotherapy are independently used to treat relapsed/refractory (R/R) lymphoma. In vitro studies suggest that the addition of HDACi to platinum-based chemotherapy is synergistic.

Patients and methods: We conducted a phase I study of romidepsin, gemcitabine, oxaliplatin and dexamethasone (Romi-GemOxD) in R/R aggressive lymphomas with an expansion cohort in T-cell lymphomas. A total of 24 patients were enrolled with median age 70; 6 patients had diffuse large B-cell lymphoma (DLBCL) and 18 patients had peripheral T-cell lymphomas (PTCL-NOS: 10; angioimmunoblastic T-cell lymphoma [AITL]: 7; ALK-negative anaplastic large cell lymphoma: 1). Patients had received a median of 2 prior lines of therapy and 10 patients were refractory to last line of therapy.

Results: Using a standard 3 + 3 dose escalation design, the maximum tolerated dose of romidepsin was determined to be 10 mg/m² in combination with GemOxD. There were no unexpected toxicities. The most common grade ≥ 3 treatment-emergent adverse events were thrombocytopenia (79%) and lymphopenia (46%). The overall response rate for Romi-GemOxD was 52% (12/23) with complete response (CR) rate of 43% (10/23). All 6 patients with AITL evaluable for efficacy achieved CR. Durable responses were seen in patients with AITL, PTCL-NOS and DLBCL. Without additional therapy, 4 patients remained in remission for more than 2 years, with 3 patients progressing at 46.5, 30.8, and 32.6 months and 1 remission ongoing at 83 months. A total of 4 patients proceeded to consolidative stem cell transplant following induction.

Conclusion: Romi-GemOxD represents a well-tolerated, time-limited, effective option for patients, particularly for those with AITL in which durable responses were seen. NCT02181218.

Keywords: Angioimmunoblastic T-cell lymphoma; Gemcitabine oxaliplatin; Histone deacetylase inhibitor; Peripheral T-cell lymphoma; Romidepsin.

Associated data

ClinicalTrials.gov/NCT02181218